BNTX BioNTech
WatchlistBioNTech News
BioNTech: Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine
6-K | BioNTech SE (0001776985) (Filer)
BioNTech: Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union
6-K | BioNTech SE (0001776985) (Filer)
BioNTech: Others
144/A | BioNTech SE (0001776985) (Subject)
BioNTech: BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer
6-K | BioNTech SE (0001776985) (Filer)
BioNTech: Quarterly Report for the Three and Six Months Ended June 30, 2023
6-K | BioNTech SE (0001776985) (Filer)
BioNTech: BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update
6-K | BioNTech SE (0001776985) (Filer)
BioNTech: BioNTech Completes Acquisition of InstaDeep
6-K | BioNTech SE (0001776985) (Filer)
BioNTech: Notice of proposed sale of securities pursuant to Rule 144
144 | BioNTech SE (0001776985) (Subject)
BioNTech: BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 program in Metastatic NSCLC
6-K | BioNTech SE (0001776985) (Filer)
BioNTech: Notice of proposed sale of securities pursuant to Rule 144
144 | BioNTech SE (0001776985) (Subject)
BioNTech: Pfizer and BioNTech Submit Applications to U.S. FDA for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine
6-K | BioNTech SE (0001776985) (Filer)
BioNTech: Pfizer and BioNTech Initiate Application to European Medicines Agency for Omicron XBB.1.5-Adapted Monovalent COVID-19 Vaccine
6-K | BioNTech SE (0001776985) (Filer)
BioNTech: BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
6-K | BioNTech SE (0001776985) (Filer)
BioNTech: BioNTech Announces $0.5 billion Share Repurchase Program
6-K | BioNTech SE (0001776985) (Filer)
BioNTech: Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with the European Commission
6-K | BioNTech SE (0001776985) (Filer)
BioNTech: Press Release: Changes in the Supervisory Board of BioNTech SE and Voting Results from the Annual General Meeting 2023
6-K | BioNTech SE (0001776985) (Filer)
BioNTech: Quarterly Report of BioNTech SE for the Three Months Ended March 31, 2023
6-K | BioNTech SE (0001776985) (Filer)
BioNTech: Quarterly Report of BioNTech SE for the Three Months Ended March 31, 2023
6-K | BioNTech SE (0001776985) (Filer)
BioNTech: BioNTech Announces First Quarter 2023 Financial Results and Corporate Update
6-K | BioNTech SE (0001776985) (Filer)
BioNTech: Invitation to the Annual General Meeting 2023 on May 25, 2023
6-K | BioNTech SE (0001776985) (Filer)